Upcoming Investor Events: Zevra Therapeutics Seeks Engagement

Author: Evelyn Baker Updated: 08-26-2025 07:45 AM

Zevra Therapeutics to Engage with Investors in September

Zevra Therapeutics, Inc. (NASDAQ: ZVRA), a company dedicated to developing innovative therapies for rare diseases, has announced its participation in two prominent conferences scheduled for September. This engagement with investors is an excellent opportunity for the company to share its vision and strategic plans.

Details of the Upcoming Conferences

Cantor Global Healthcare Conference

The first event on the calendar is the Cantor Global Healthcare Conference, taking place on a Wednesday in early September at 11:30 a.m. ET. This event will provide Zevra's leadership team the platform to introduce their latest advancements and discuss their strategies aimed at addressing unmet medical needs.

H.C. Wainwright 27th Annual Global Investment Conference

Following the Cantor Global Healthcare Conference, Zevra Therapeutics will be present at the H.C. Wainwright 27th Annual Global Investment Conference. This conference is scheduled for the following Monday at 10:00 a.m. ET and aims to gather investors and industry leaders to explore the latest developments in biotechnology and pharmaceuticals.

One-on-One Meetings

Beyond the scheduled presentations, management will also be available for individual meetings with registered attendees. These interactions can be invaluable for investors seeking deeper insights into Zevra's operations and strategic priorities.

Webcasts and Further Information

The live webcasts of the presentations will be accessible on the Investor Relations section of Zevra's website, providing a convenient way for investors to stay informed about the company’s initiatives and performance.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. operates at the forefront of rare disease therapy development. Its mission revolves around transforming the landscape of treatment options available to patients with rare diseases that often lack effective therapies. Through a combination of scientific innovation, comprehensive data analysis, and a deep understanding of patient needs, Zevra strives to create impactful solutions that address significant gaps in medical care.

Investing in Innovation

As Zevra actively participates in these investor conferences, the outlook remains positive. The ongoing dialogues between Zevra and its investors signify a shared commitment to advancing therapeutic solutions for challenging conditions. This proactive engagement reflects Zevra's dedication to transparency and collaboration in the pursuit of innovative healthcare solutions.

Contact Information

Interested parties can reach out to the company directly for inquiries.

Zevra Contact:

Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com

Frequently Asked Questions

What investor conferences is Zevra participating in September?

Zevra is participating in the Cantor Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference.

What is the focus of Zevra Therapeutics?

Zevra Therapeutics focuses on developing therapies for rare diseases with limited or no treatment options.

How can investors access the webcasts?

Investors can access the live webcasts through the Investor Relations section of Zevra's website.

Will there be opportunities for one-on-one meetings?

Yes, Zevra’s management will be available for one-on-one meetings with registered conference attendees.

How can I contact Zevra Therapeutics?

Contact Nichol Ochsner via phone at +1 (732) 754-2545 or via email at nochsner@zevra.com.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.